1. Pink Sheet

EMA to make public side-effects in EudraVigilance database by end of 2011

 
• By Vibha Sharma

The European Medicines Agency by the end of 2011 plans to start granting public access to information in its EudraVigilance database on potential side-effects of certain human drugs1.

The European Medicines Agency by the end of 2011 plans to start granting public access to information in its EudraVigilance database on potential side-effects of certain human drugs1.

The EMA says monthly summary reports of suspected adverse drug reactions information held in the database for all human medicines authorised through the centralised procedure will be made available to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.